Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Common Equity (2020 - 2025)

Historic Common Equity for Mirum Pharmaceuticals (MIRM) over the last 6 years, with Q3 2025 value amounting to $292.0 million.

  • Mirum Pharmaceuticals' Common Equity rose 2586.89% to $292.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $292.0 million, marking a year-over-year increase of 2586.89%. This contributed to the annual value of $225.6 million for FY2024, which is 926.13% down from last year.
  • Per Mirum Pharmaceuticals' latest filing, its Common Equity stood at $292.0 million for Q3 2025, which was up 2586.89% from $255.2 million recorded in Q2 2025.
  • In the past 5 years, Mirum Pharmaceuticals' Common Equity ranged from a high of $292.0 million in Q3 2025 and a low of $56.4 million during Q3 2021
  • In the last 5 years, Mirum Pharmaceuticals' Common Equity had a median value of $169.3 million in 2022 and averaged $177.7 million.
  • In the last 5 years, Mirum Pharmaceuticals' Common Equity crashed by 5310.3% in 2021 and then soared by 20019.33% in 2022.
  • Mirum Pharmaceuticals' Common Equity (Quarter) stood at $120.2 million in 2021, then rose by 18.16% to $142.0 million in 2022, then soared by 75.07% to $248.7 million in 2023, then dropped by 9.26% to $225.6 million in 2024, then grew by 29.43% to $292.0 million in 2025.
  • Its Common Equity stands at $292.0 million for Q3 2025, versus $255.2 million for Q2 2025 and $233.3 million for Q1 2025.